Business Wire

RPS Diagnostics Announces Canadian Approval of FebriDx® Test to Help Rapidly Differentiate Viral from Bacterial Acute Respiratory Infection at the Point of Care

SARASOTA, Fla.--(BUSINESS WIRE)--RPS Diagnostics, Inc. (RPS®) today announces that Health Canada issued a Medical Device License for FebriDx® – a rapid, in-office test that uses a fingerstick blood ...
Sarasota Magazine

Sarasota's RPS Diagnostics Merges With California Company

RPS Diagnostics, a Sarasota-based commercial diagnostic developer, manufacturer, and marketer of point-of-care diagnostic tests, and Lumos Diagnostics, a California-based, full-service, point-of-care ...
Medscape

FDA Approvals: RPS Adeno Detector, Elecsys NT-proBNP Test, TBA Assay

Jan. 6, 2006 — The US Food and Drug Administration (FDA) approved in 2005 a rapid point-of-care test for adenovirus in tear fluid as an aid in the differential diagnosis of acute conjunctivitis; a new ...
PR Newswire

RPS Announces CE Mark of Rapid, Point-Of-Care Test to Help Detect the Body's Immune Response to Viral And Bacterial Infections - FebriDx™

FebriDx is a rapid, disposable, in-office test that helps identify and differentiate a clinically significant immune response to viral and/or bacterial acute febrile respiratory infection at the point ...
Sarasota Herald-Tribune

RPS Diagnostics merges to support product launch

LAKEWOOD RANCH — Local biotech company RPS Diagnostics has merged with a California firm that will focus on the international launch of RPS's infections test. Lumos Diagnostics has acquired all of the ...